A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy.
Latest Information Update: 18 Feb 2019
Price :
$35 *
At a glance
- Drugs Luminespib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 03 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned initiation date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.